257 related articles for article (PubMed ID: 33415542)
1. Early Physiological and Cellular Indicators of Cisplatin-Induced Ototoxicity.
Chen Y; Bielefeld EC; Mellott JG; Wang W; Mafi AM; Yamoah EN; Bao J
J Assoc Res Otolaryngol; 2021 Apr; 22(2):107-126. PubMed ID: 33415542
[TBL] [Abstract][Full Text] [Related]
2. Changing the time intervals between cisplatin cycles alter its ototoxic side effect.
Bielefeld EC; Gonzalez A; DeBacker JR
Hear Res; 2021 May; 404():108204. PubMed ID: 33618164
[TBL] [Abstract][Full Text] [Related]
3. Degranulation of Murine Resident Cochlear Mast Cells: A Possible Factor Contributing to Cisplatin-Induced Ototoxicity and Neurotoxicity.
Karayay B; Olze H; Szczepek AJ
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902051
[TBL] [Abstract][Full Text] [Related]
4. Are There Cochlear Dead Regions Involved in Hearing Loss after Cisplatin Ototoxicity?
Schultz C; Pecora Liberman PH; Schmidt Goffi-Gomez MV
Audiol Neurootol; 2019; 24(5):253-257. PubMed ID: 31661686
[TBL] [Abstract][Full Text] [Related]
5. Circadian vulnerability of cisplatin-induced ototoxicity in the cochlea.
Tserga E; Moreno-Paublete R; Sarlus H; Björn E; Guimaraes E; Göritz C; Cederroth CR; Canlon B
FASEB J; 2020 Oct; 34(10):13978-13992. PubMed ID: 32840016
[TBL] [Abstract][Full Text] [Related]
6. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect.
Bielefeld EC; Tanaka C; Chen GD; Coling D; Li M; Henderson D; Fetoni AR
Anticancer Drugs; 2013 Jan; 24(1):43-51. PubMed ID: 22828384
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cochlear toxicity in response to chronic 3,3'-iminodipropionitrile in mice reveals early and reversible functional loss that precedes overt histopathology.
Greguske EA; Llorens J; Pyott SJ
Arch Toxicol; 2021 Mar; 95(3):1003-1021. PubMed ID: 33495873
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity.
Borse V; Al Aameri RFH; Sheehan K; Sheth S; Kaur T; Mukherjea D; Tupal S; Lowy M; Ghosh S; Dhukhwa A; Bhatta P; Rybak LP; Ramkumar V
Cell Death Dis; 2017 Jul; 8(7):e2921. PubMed ID: 28703809
[TBL] [Abstract][Full Text] [Related]
9. Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity.
Al Aameri RFH; Alanisi EMA; Oluwatosin A; Al Sallami D; Sheth S; Alberts I; Patel S; Rybak LP; Ramkumar V
Front Immunol; 2023; 14():1125948. PubMed ID: 37063917
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-induced ototoxicity: From signaling network to therapeutic targets.
Wang X; Zhou Y; Wang D; Wang Y; Zhou Z; Ma X; Liu X; Dong Y
Biomed Pharmacother; 2023 Jan; 157():114045. PubMed ID: 36455457
[TBL] [Abstract][Full Text] [Related]
11. The ototoxicity of 3,3'-iminodipropionitrile: functional and morphological evidence of cochlear damage.
Crofton KM; Janssen R; Prazma J; Pulver S; Barone S
Hear Res; 1994 Nov; 80(2):129-40. PubMed ID: 7896571
[TBL] [Abstract][Full Text] [Related]
12. Chronotolerance for cisplatin ototoxicity in the rat.
Bielefeld EC; Markle A; DeBacker JR; Harrison RT
Hear Res; 2018 Dec; 370():16-21. PubMed ID: 30253329
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin ototoxicity involves organ of Corti, stria vascularis and spiral ganglion: modulation by alphaMSH and ORG 2766.
Hamers FP; Wijbenga J; Wolters FL; Klis SF; Sluyter S; Smoorenburg GF
Audiol Neurootol; 2003; 8(6):305-15. PubMed ID: 14566101
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development.
Pasdelou MP; Byelyayeva L; Malmström S; Pucheu S; Peytavy M; Laullier H; Hodges DB; Tzafriri AR; Naert G
Front Mol Neurosci; 2024; 17():1379743. PubMed ID: 38756707
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin Toxicology: The Role of Pro-inflammatory Cytokines and GABA Transporters in Cochlear Spiral Ganglion.
Gao D; Yu H; Li B; Chen L; Li X; Gu W
Curr Pharm Des; 2019; 25(45):4820-4826. PubMed ID: 31692421
[TBL] [Abstract][Full Text] [Related]
16. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity.
Kim KH; Lee B; Kim YR; Kim MA; Ryu N; Jung DJ; Kim UK; Baek JI; Lee KY
Cell Death Dis; 2018 Aug; 9(8):827. PubMed ID: 30068942
[TBL] [Abstract][Full Text] [Related]
17. Lovastatin protects against cisplatin-induced hearing loss in mice.
Fernandez K; Spielbauer KK; Rusheen A; Wang L; Baker TG; Eyles S; Cunningham LL
Hear Res; 2020 Apr; 389():107905. PubMed ID: 32062294
[TBL] [Abstract][Full Text] [Related]
18. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
19. Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity.
Jamesdaniel S; Rathinam R; Neumann WL
Redox Biol; 2016 Dec; 10():257-265. PubMed ID: 27821327
[TBL] [Abstract][Full Text] [Related]
20. Effects of lifetime noise exposure on the middle-age human auditory brainstem response, tinnitus and speech-in-noise intelligibility.
Valderrama JT; Beach EF; Yeend I; Sharma M; Van Dun B; Dillon H
Hear Res; 2018 Aug; 365():36-48. PubMed ID: 29913342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
